An ALLG Window Study of Acalabrutinib plus Rituximab followed by Cytarabine, Oxaliplatin, Dexamethasone and Rutixumab (R-DHAOx) + Autologous Stem Cell Transplant (ASCT) in newly diagnosed fit Mantle Cell Lymphoma patients.
Professor Chan Cheah
Australasian Leukaemia & Lymphoma Group
- Mantle Cell Lymphoma (MCL)
This trial is for patients <70 years of age with newly diagnosed mantle cell lymphoma who are otherwise in good health. Patients will begin the first part of treatment for two months which consists of rituximab and acalabrutinib. Rituximab is an antibody that is given as an intravenous infusion and targets the CD20 protein to trigger cell death. Acalabrutinib is a tablet taken by mouth twice daily and works by blocking a protein called BTK which leads to lymphoma cell death. Patients will also receive a standard chemotherapy program called R-DHAOx intravenously followed high dose chemotherapy and stem cell transplant. Patients will enter maintenance phase with acalabrutinib and rituximab.
Include but not limited to:
- Aged 18-70 years
- Fit for autologous stem cell transplant
- Histologically confirmed CD20+ve MCL (WHO criteria)
- No prior lymphoma treatment
- Stage II-IV disease (or Stage I with bulk >7cm)
- PET/CT avid disease at baseline
- Adequate BM, renal, hepatic and cardiac function